A more comprehensive multiethnic genetic risk score strongly predicted new cases of type 2 diabetes, including for people without the traditional risk factors of excess fat and high blood sugar.

Evolocumab is prescribed as an adjunct to a low-fat diet and other cholesterol medications in treating patients with high low-density lipoprotein (LDL) cholesterol, total cholesterol, heterozygous ...

Pfizer is in a three-way fight to bring the first PCSK9 inhibitor to market with Amgen and Sanofi/Regeneron whose respective evolocumab and alirocumab candidates have already been filed for ...

A double-blind, randomized, placebo-controlled, multicenter study to evaluate the impact of evolocumab on major cardiovascular events in patients at high cardiovascular risk without prior myocardial ...

Company provided an update on the obicetrapib clinical development program and outlined its strategic priorities for ...